Edwards Lifesciences Beats Revenue Estimates at $1.72 Billion; Raises Outlook
The company raised its 2026 sales growth guidance to about 11.5% and its adjusted EPS guidance to $2.97 to $3.05.
Edwards Lifesciences EW
Edwards Lifesciences Corp · NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies
$99.37+4.39%close on Nov. 4, 2026 · volume 7.8M · Yahoo Finance
Price, last 52 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 8, 2026 | Daniel J. Lippis CVP, TAVR | Sold 10b5-1 plan | 619 | $85.65 | $53,017 |
| Sept. 11, 2026 | Daniel J. Lippis CVP, TAVR | Sold 10b5-1 plan | 619 | $87.51 | $54,169 |
| Aug. 31, 2026 | Andrew M. Dahl SVP, Corporate Controller | Sold | 544 | $91.06 | $49,534 |
| Aug. 28, 2026 | Annette Bruls CVP, EMEACLA | Sold | 2,644 | $89.98 | $237,907 |
| Aug. 26, 2026 | Daveen Chopra CVP, TMTT, Surgical & IHFM | Sold | 31,800 | $91.02 $90.99-$91.76 | $2.89 million |
| Aug. 26, 2026 | Wayne Markowitz CVP, JAPAC | Sold | 1,240 | $91.47 | $113,417 |
| Aug. 11, 2026 | Daniel J. Lippis CVP, TAVR | Sold 10b5-1 plan | 619 | $92.03 | $56,967 |
| July 30, 2026 | Wayne Markowitz CVP, JAPAC | Sold | 146 | $86.03 | $12,588 |
| July 28, 2026 | Wayne Markowitz CVP, JAPAC | Sold | 9,628 | $85.06 | $818,958 |
| July 27, 2026 | Bernard J. Zovighian CEO, director · indirect | Sold | 2,921 | $83.93 | $245,134 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 17 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedEdwards Lifesciences Q3 2026 adjusted EPS of $0.80 beats $0.74 consensus on $1.72 billion sales; raises 2026 sales, TAVR, TMTT and adjusted EPS guidance